----
Current ValuationThe current P/E ratio is -37.11, within the reasonable range, cheaper than 77.36% of the time in the past 1 years, and the industry ranks 56/74, the industry Median --.
-37.11xP/E
$10.71Stock price
$-0.29Earnings per share
-37.11xP/E
Stock price$10.71Earnings per share$-0.29
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -29.26x
- Typical range
- -37.83x–-20.72x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -50.52x | 2.99% | $22.91B |
HIMSUSHims & Hers Health | -48.41x | 209.86% | $6.88B |
RDNTUSRadnet | -261.93x | 128.00% | $5.53B |
WGSUSGeneDx | -20.05x | 359.59% | $2.13B |
NEOUSNeogenomics | -40.87x | 64.43% | $2.12B |
AGLUSagilon health | -6.03x | 92.48% | $1.40B |
INNVUSInnovage | -484.06x | 2,301.70% | $1.23B |
OPKUSOpko Health | -14.95x | 25.44% | $1.09B |
LMRIUSLumexa Imaging | -37.11x | 145.51% | $1.03B |
CSTLUSCastle Biosciences | -52.49x | 52.61% | $1.02B |
FLGTUSFulgent Genetics | -6.71x | 42.64% | $566.26M |
GMRSUSGMR Solutions | -7.28x | 91.45% | $551.02M |
AONCUSAmerican Oncology Network | -- | -- | $371.06M |
PREUSPrenetics Global | -7.44x | 16.63% | $349.73M |
BDSXUSBiodesix | -10.63x | 42.77% | $295.01M |
GAMGUSGlobal Asset Management Group, Inc. | -375.03x | -- | $211.68M |
NAKAUSNakamoto | -0.41x | 102.50% | $171.25M |
AIRSUSAirSculpt Tech | -11.42x | 33.33% | $134.10M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
PARKUSPark Dental Partners | -27.62x | -- | $97.63M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
